On April 19, 2019, Srinivas Akkaraju, M.D., Ph.D., informed Principia Biopharma Inc. that he does not intend to stand for reelection to the company's Board of Directors at the company's 2019 Annual Meeting of Stockholders. Dr. Akkaraju's intent not to stand for reelection to the Board is not the result of a disagreement with the company on any matter relating to the company's operations, policies or practices. On April 16, 2019, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Martin Babler as President of the Company, effective immediately. Mr. Babler will also continue to serve as Chief Executive Officer. Mr. Babler, age 54, has served as the company's Chief Executive Officer since April 2011. From December 2007 to April 2011, Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics Inc. On April 16, 2019, the Board appointed Shao-Lee Lin, M.D., Ph.D., as a Class I director of the company, with a term of office expiring at the 2019 Annual Meeting. Concurrent with her appointment to the Board, Dr. Lin was also appointed to serve as a member of the Nominating and Corporate Governance Committee. Dr. Akkaraju and Alan Colowick, M.D., M.P.H. will continue as members of the Nominating and Corporate Governance Committee, with Dr. Akkaraju stepping down at the 2019 Annual Meeting.